Drug Trial Radar · NCT07194850
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Oct 2028
Study completion Oct 2030
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Sep 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP). The study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second year (OLTP2). After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancejunior
Conditions
- Immune Thrombocytopenia (ITP)
- ITP - Immune Thrombocytopenia
- ITP
- Immune Thrombocytopenic Purpura
- Immune Thrombocytopenic Purpura ( ITP )
- Idiopathic Thrombocytopenic Purpura
- Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
Efgartigimod IVBiological
Intravenous infusion of efgartigimod
Placebo IVOther
Intravenous infusion of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efgartigimod serum concentrations in the DBTPTime frame: Up to 24 weeks
- Total IgG levels in the DBTPTime frame: Up to 24 weeks
Locations
28 sites in 10 countries. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfants
Bordeaux, France · Recruiting
Centre Hospitalier Universitaire de Grenoble - Hopital Couple - Enfant
La Tronche, France · Recruiting
CHU de Nancy Hopitaux de Brabois
Vandœuvre-lès-Nancy, France · Recruiting
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)
Berlin, Germany · Recruiting
Universitaetsklinikum Freiburg Kinder - Kinder- und Jugendklinik
Freiburg im Breisgau, Germany · Recruiting
Gaslini Children's Hospital
Genoa, Italy · Recruiting
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy · Recruiting
Bambino Gesu Children's Hospital
Roma, Italy · Recruiting
A.O.U. Citta della Salute e della Scienza di Torino - Ospedale Infantile Regina Margherita
Torino, Italy · Recruiting
Saitama Prefectural Children's Medical Center
Saitama, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Hyogo Prefectural Kobe Children's Hospital
Kobe, Hyōgo, Japan · Recruiting
Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
Osaka, Osaka, Japan · Recruiting
Vilnius University Hospital Santaros Klinikos, Children's Hospital
Vilnius, Lithuania · Recruiting
Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny nr 4
Lodz, Poland · Recruiting
Uniwersytecki Szpital Dzieciecy w Lublinie
Lublin, Poland · Recruiting
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
Warsaw, Poland · Recruiting
Institutul Clinic Fundeni
Bucharest, Romania · Recruiting
Institute Of Mother And Child Healthcare Of Serbia Dr Vukan Cupic
Belgrade, Serbia · Recruiting
University Clinical Centre of Kragujevac
Kragujevac, Serbia · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Sant Joan de Deu Barcelona
Esplugues de Llobregat, Spain · Recruiting
Hospital Infantil Universitario Nino Jesus (HIUNJS)
Madrid, Spain · Recruiting
Hospital Materno-Infantil Universitario Gregorio Maranon
Madrid, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Cardiff and Vale NHS Trust - University Hospital of Wales (UHW)
Cardiff, United Kingdom · Recruiting
The Royal Hospital for Children - Glasgow Health Board
Glasgow, United Kingdom · Recruiting
Royal Manchester Children's Hospital - Manchester University NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.